Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30353618.
- Also identified by DOI 10.1002/stem.2933 and PMC identifier 6368859.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hematopoietic stem and progenitor cells (HSPCs) are the progenitor cells that can regenerate the entire blood compartment, including the immune system. Recent studies have unearthed considerable immune-modulating potential of these cells. They can migrate through chemotactic gradients, differentiate into functional immune cells, and crosstalk with immune cells during infections, autoimmune diseases, and cancers. Although the primary role of HSPCs during solid malignancies is considered immunosuppressive, recent studies have discovered immune-activating HSPCs and progeny. In this review, we will discuss the recent evidence that HSPCs act as immunomodulators during solid cancers and highlight the future directions of discovery. Stem Cells 2019;37:166-175.
Medical subject headings
- Hematopoietic Stem Cells
- Immunity
- Immunotherapy
- Neoplasms
- Stem Cells